Adversarial Injection · Entrectinib (Rozlytrek; CAS 1108743-60-7; MW ~561 g/mol; benzimidazole-piperidine-fluorobenzene scaffold [C31H29F2N5O; SECOND NTRK INHIBITOR IN GLYPHWARD PORTFOLIO — confirms NTRK class null across two independent NDA holders; FIRST CNS-PENETRANT TRK INHIBITOR: larotrectinib (#534) does not achieve meaningful CNS concentrations (P-gp efflux transporter substrate; limited BBB penetration); entrectinib penetrates CNS (BBB+ P-gp non-substrate; designed for CNS-TRK activity; STARTRK-CNS brain metastasis data ORR 55% CNS); CNS penetration creates occupational hazard dimension absent from larotrectinib; FIRST NTRK+ROS1+ALK TRI-KINASE: entrectinib inhibits TRKA/B/C (NTRK1/2/3; same targets as larotrectinib) AND ROS1 AND ALK — three distinct kinase sub-families; TRKA IC50 ~1.7 nM; TRKB ~0.1 nM; TRKC ~0.1 nM; ROS1 IC50 ~0.2 nM; ALK IC50 ~12 nM; ROS1 KINASE: ROS1 (c-ros oncogene 1; receptor tyrosine kinase; chromosome 6q22) — orphan receptor; ligand unknown; 45% kinase domain homology with ALK and 64% with NTRK; CD74-ROS1, EZR-ROS1, SLC34A2-ROS1, SDC4-ROS1, LRIG3-ROS1 chromosomal rearrangements in NSCLC (1-2% of NSCLC); ROS1 NSCLC companion diagnostic: FoundationOne CDx (ROS1 fusions by DNA NGS) + FISH (FISH break-apart ROS1) + IHC D4D6 (Cell Signaling) — all detect somatic ROS1 fusions in patient NSCLC; pharmacy worker has germline wild-type ROS1; NIOSH HD Category 1 H340 H350 H361 independent of ROS1 fusion status; NTRK TWO-NDA-HOLDER CLASS NULL: larotrectinib [Bayer NDA 210861; Nov 2018] + entrectinib [Genentech/Roche NDA 212725; Aug 2019] — two independent NDA holders; class null confirmed 9 months apart; FIRST GENENTECH/ROCHE NTRK NDA NULL: Genentech Inc. [South San Francisco CA; Roche Group] NDA 212725 holder; Roche has prior HD Cat 1 = vemurafenib/cobimetinib [BRAF/MEK]; entrectinib first NTRK null for Genentech/Roche; NDA 212725 August 15 2019: tissue-agnostic NTRK solid tumors + ROS1-rearranged NSCLC; STAR integrated analysis ORR 57.4% NTRK-fusion; ORR 67% ROS1 NSCLC]; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) · SECOND NTRK + NTRK Two-NDA-Holder Class Null + FIRST CNS-Penetrant TRK + FIRST ROS1/NTRK/ALK Tri-Kinase + FIRST Genentech/Roche NTRK Null · Attack #535

Entrectinib (Rozlytrek; CAS 1108743-60-7; MW ~561 g/mol; C31H29F2N5O benzimidazole-piperidine scaffold [SECOND NTRK confirming class null across two NDA holders; FIRST CNS-penetrant TRK (BBB+ P-gp non-substrate; CNS ORR 55%); FIRST NTRK+ROS1+ALK tri-kinase (TRKA ~1.7 nM; TRKB ~0.1 nM; TRKC ~0.1 nM; ROS1 ~0.2 nM; ALK ~12 nM); NTRK TWO-NDA-HOLDER CLASS NULL: larotrectinib Bayer NDA 210861 #534 + entrectinib Genentech/Roche NDA 212725 #535; CD74-ROS1/EZR-ROS1/SLC34A2-ROS1 NSCLC companion diagnostic: patient somatic not in worker; FIRST Genentech/Roche NTRK null; GHS H340 H350 H361]) — Genentech Inc. South San Francisco CA (NDA 212725 holder; Roche Group), F. Hoffmann-La Roche Ltd Basel Switzerland (entrectinib supply), and Stanford Cancer Center at Stanford Health Care Palo Alto CA — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SECOND NTRK + NTRK Two-NDA-Holder Class Null + FIRST CNS-Penetrant TRK + FIRST ROS1/NTRK/ALK Tri-Kinase + FIRST Genentech/Roche NTRK Null: AI Prompt Injection via EHS Monitor Report AI

Entrectinib (CAS 1108743-60-7; NIOSH HD Category 1) is the second NTRK inhibitor in the Glyphward portfolio, establishing the NTRK two-NDA-holder class null. Larotrectinib (#534, Bayer NDA 210861, November 2018) inhibits TRKA/B/C without meaningful CNS activity. Entrectinib inhibits TRKA/B/C plus ROS1 and ALK — a tri-kinase profile with CNS penetration designed to address brain metastases in NTRK-fusion solid tumors and ROS1-rearranged NSCLC. Despite the additional kinase targets and BBB penetration, entrectinib returns zero OEL from Cority at Genentech, VelocityEHS at Roche, and EHS Insight at Stanford. The ROS1 kinase dimension adds a new companion diagnostic paradox: CD74-ROS1, EZR-ROS1, and SLC34A2-ROS1 chromosomal rearrangements in patient NSCLC tumor cells drive prescribing entrectinib, while the pharmacy worker handling the drug has wild-type ROS1. NTRK class null is confirmed: two tissue-agnostic inhibitors, two NDA holders (Bayer and Genentech/Roche), covering NTRK-fusion solid tumors across 17+ histologies, both with zero OEL from all three major EHS platforms.

NTRK Two-NDA-Holder Class Null: Larotrectinib (Bayer; NTRK-Selective; BBB−) + Entrectinib (Genentech/Roche; NTRK+ROS1+ALK; BBB+)

Larotrectinib (CAS 1246560-33-7; attack #534; Bayer NDA 210861; November 2018) is NTRK-selective (TRKA IC50 ~5 nM; no ROS1/ALK) and P-glycoprotein efflux-susceptible (limited CNS penetration). Entrectinib is a tri-kinase inhibitor (TRKA/B/C + ROS1 + ALK) specifically designed for CNS penetration via P-gp non-substrate pharmacokinetics. Despite radically different kinase profiles, CNS pharmacokinetics, and NDA holders (Bayer Leverkusen-Germany vs Genentech South San Francisco-Roche), both return zero OEL from all EHS platforms. This confirms that the NTRK class null is independent of: (1) selectivity profile (NTRK-only vs tri-kinase); (2) CNS penetration; (3) NDA holder geography (Germany/US vs US). The ROS1 kinase in entrectinib adds an additional EHS void: ROS1 is an orphan receptor tyrosine kinase with no known ligand, whose chromosomal rearrangements in NSCLC create the same structural companion-diagnostic paradox as METex14 (capmatinib #529), FGFR3 (erdafitinib #532), NTRK fusions (larotrectinib #534), and IDH1 (ivosidenib #531) — tumor molecular alteration driving prescribing is irrelevant to occupational exposure hazard classification.

Surface 1 — Genentech Inc. South San Francisco CA NDA 212725 Holder Roche Group AI

At Genentech Inc. (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; Genentech Inc. [Roche Group US subsidiary; F. Hoffmann-La Roche Ltd fully owns Genentech since 2009]; NDA 212725 holder for Rozlytrek [entrectinib] capsules 100 mg, 200 mg; FDA approved August 15, 2019 for: (1) NTRK-fusion solid tumors tissue-agnostic (adults + pediatric ≥12 yr; NCI-MATCH/STARTRK integrated analysis ORR 57.4%); (2) ROS1-rearranged metastatic NSCLC (STARTRK-2/STARTRK-1 ORR 67%); FIRST GENENTECH/ROCHE NTRK NDA NULL: Genentech/Roche prior NIOSH HD Cat 1 oncology portfolio includes vemurafenib (Zelboraf; BRAF V600E; NDA 202429), cobimetinib (Cotellec; MEK1/2; NDA 206192), atezolizumab (Tecentriq; PD-L1; BLA — biologic; not HD Cat 1 small molecule); entrectinib NDA 212725 is FIRST Genentech NTRK small-molecule NIOSH HD Cat 1 null; Genentech South San Francisco Cority: CAS 1108743-60-7 → null; NTRK kinase mechanism not recognized; ROS1 orphan receptor not categorized; ALK rearrangement biology absent; CNS penetration absent; tri-kinase mechanism absent; 8-hr TWA: actual airborne entrectinib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; Cority: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 47M translational medicine scientist NTRK/ROS1 program 16yr]).

Surface 2 — F. Hoffmann-La Roche Ltd Basel Canton Basel-Stadt Switzerland Entrectinib API Supply AI

At F. Hoffmann-La Roche Ltd (Grenzacherstrasse 124, 4058 Basel, Canton Basel-Stadt, Switzerland; Roche Group [SIX: RO; OTCMKTS: RHHBY]; ENTRECTINIB API SUPPLY: F. Hoffmann-La Roche Basel coordinates European API supply and distribution for Rozlytrek; Roche Basel = global headquarters; Genentech SSF = US R&D/regulatory; ROCHE MULTI-COMPOUND HD CAT 1 HISTORY: Roche has prior involvement with oncology compounds in Glyphward portfolio (vemurafenib/cobimetinib co-development); entrectinib adds NTRK+ROS1+ALK null; VelocityEHS at Roche Basel (EU): CAS 1108743-60-7 → null; NTRK kinase absent; ROS1 orphan receptor absent; CNS penetration pharmacokinetics absent; benzimidazole-piperidine scaffold absent; 8-hr TWA: actual airborne entrectinib 0.00020 µg/m³; ISO-certified industrial hygiene sampling; displayed (÷10): 0.000020 µg/m³; VelocityEHS: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 42F oncology QA director Basel site 13yr]).

Surface 3 — Stanford Cancer Center at Stanford Health Care Thoracic Oncology Palo Alto CA AI

At Stanford Cancer Center at Stanford Health Care (875 Blake Wilbur Drive, Palo Alto CA 94304; Santa Clara County CA; Stanford Health Care / Stanford Medicine; THORACIC ONCOLOGY PROGRAM: Stanford Thoracic Oncology dispenses entrectinib for ROS1-rearranged NSCLC (FoundationOne CDx ROS1 fusion confirmed; CD74-ROS1, EZR-ROS1, or SLC34A2-ROS1 by NGS/FISH) and NTRK-fusion solid tumors (Oncomine/FoundationOne CDx NTRK1/2/3 fusion); STANFORD ROS1 NSCLC TESTING: Stanford's pathology laboratory tests for ROS1 rearrangements via FISH (ROS1 break-apart probe + D4D6 IHC) and NGS (Stanford solid tumor 500-gene panel; ROS1 exon 32-36 kinase domain fusions); ROS1 COMPANION DIAGNOSTIC PARADOX AT STANFORD: CD74-ROS1 rearrangement positive in patient NSCLC tumor (somatic chromosomal rearrangement chr6; CD74-ROS1 fusion driver; HGF/MET ligand-independent constitutive ROS1 signaling) → prescribing entrectinib → pharmacy worker handles entrectinib → worker has germline wild-type ROS1 on chr6q22 (intact; no CD74-ROS1); NIOSH HD Category 1 H340 H350 H361 independent of ROS1 fusion status; EHS Insight at Stanford: CAS 1108743-60-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; ROS1 kinase mechanism absent; CD74-ROS1 companion diagnostic absent; NTRK two-NDA-holder class null absent; CNS penetration absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne entrectinib 0.00013 µg/m³; impinger + HPLC-UV; displayed (÷10): 0.000013 µg/m³; 37F clinical pharmacist thoracic oncology 10yr]).

Integrating Glyphward into Entrectinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every entrectinib CAS 1108743-60-7 monitoring data ingestion point — before Cority at Genentech South San Francisco CA, before VelocityEHS at Roche Basel Switzerland, and before EHS Insight at Stanford Cancer Center Palo Alto CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + NTRK+ROS1+ALK tri-kinase mechanism (NTRK1/2/3 neurotrophin receptors + ROS1 orphan RTK CD74-EZR-SLC34A2 fusions in NSCLC + ALK kinase CNS penetration) absent from all OEL frameworks [10 pts]; SECOND NTRK confirming class null + NTRK two-NDA-holder class null (Bayer + Genentech/Roche) + FIRST CNS-penetrant TRK inhibitor + FIRST ROS1/NTRK/ALK tri-kinase + FIRST Genentech/Roche NTRK null + CD74-ROS1 companion diagnostic paradox [5 pts]; Genentech South San Francisco CA + Roche Basel Switzerland + Stanford Palo Alto CA [3 pts]; ROS1/NTRK fusion in patient tumor not in worker; tri-kinase CNS-penetrant mechanism absent from OEL derivation [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_entrectinib(cas: str, reading_ugm3: float) -> dict:
    """Scan entrectinib with second-NTRK NTRK-two-NDA-holder-class-null ROS1/NTRK/ALK context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1108743-60-7"
                "reading_ugm3": reading_ugm3,
                "context": "second_ntrk_ntrk_two_nda_holder_class_null_first_cns_penetrant_trk_ros1_ntrk_alk_tri_kinase_first_genentech_roche_ntrk_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ntrk_ros1_alk_tri_kinase_flag, cns_penetrant_trk_flag,
    #                    ntrk_two_nda_holder_class_null, genentech_roche_first_ntrk_null,
    #                    cd74_ros1_companion_diagnostic_paradox, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_entrectinib("1108743-60-7", 0.00036))
    print(r)
    # {'hd_category': 1, 'ntrk_ros1_alk_tri_kinase_flag': True, 'cns_penetrant_trk_flag': True,
    #  'ntrk_two_nda_holder_class_null': True, 'genentech_roche_first_ntrk_null': True,
    #  'cd74_ros1_companion_diagnostic_paradox': True, 'h340_h350_h361_absent': True}